Get the Stockscreener App
5.57
2.77%
0.15
After Hours:
5.51
-0.06
-1.08%
Mannkind Corp stock is traded at $5.57, with a volume of 4.16M.
It is up +2.77% in the last 24 hours and up +52.19% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$5.42
Open:
$5.4
24h Volume:
4.16M
Relative Volume:
1.04
Market Cap:
$1.71B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
111.40
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
+0.54%
1M Performance:
+52.19%
6M Performance:
+6.91%
1Y Performance:
-10.16%
1-Day Range:
$5.376
$5.60
1-Week Range:
$5.36
$5.705
52-Week Range:
$3.3812
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.57 | 1.71B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
Jacobs Levy Equity Management Inc. Has $10.21 Million Stake in MannKind Corporation $MNKD - MarketBeat
MannKind Corporation $MNKD Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Analysts Set MannKind Corporation (NASDAQ:MNKD) Target Price at $10.71 - MarketBeat
MannKind Corporation $MNKD Shares Sold by Nitorum Capital L.P. - MarketBeat
PDT Partners LLC Acquires New Holdings in MannKind Corporation $MNKD - MarketBeat
MannKind at Morgan Stanley Conference: Strategic Diversification Unveiled - Investing.com
MannKind at H.C. Wainwright: Focus on Pipeline Progress By Investing.com - Investing.com South Africa
MannKind at H.C. Wainwright: Focus on Pipeline Progress - Investing.com
Northern Trust Corp Sells 77,985 Shares of MannKind Corporation $MNKD - MarketBeat
Can MannKind Corporation navigate macro headwindsTrade Exit Report & Verified Swing Trading Watchlist - Lancaster City Council
MannKind (MNKD): A Fresh Look at Valuation Following New United Therapeutics Deal Expansion - Yahoo Finance
MannKind (NASDAQ:MNKD) Price Target Raised to $10.00 - MarketBeat
MannKind (NASDAQ:MNKD) Shares Gap Up After Analyst Upgrade - MarketBeat
HC Wainwright Boosts MannKind (NASDAQ:MNKD) Price Target to $11.00 - MarketBeat
What to expect from MannKind Corporation in the next 30 days2025 Analyst Calls & AI Driven Stock Reports - Newser
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline - MSN
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
MannKind Gets A Price Bump As Pipeline Progresses - Finimize
Can MannKind Corporation grow without external fundingJuly 2025 Review & Stock Market Timing Techniques - خودرو بانک
Can MannKind Corporation outperform in the next rallyJuly 2025 Fed Impact & Short-Term Trading Alerts - خودرو بانک
Can trapped investors hope for a rebound in MannKind CorporationWeekly Risk Summary & AI Enhanced Trading Signals - Newser
MannKind Corporation stock prediction for this weekMarket Risk Analysis & High Conviction Investment Ideas - Newser
What candlestick patterns are forming on MannKind CorporationWatch List & Free Verified High Yield Trade Plans - Newser
MannKind at Cantor Global Healthcare Conference: Strategic Growth Insights - Investing.com
Has MannKind Corporation formed a bullish divergenceJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-09-04 00:37:09 - Newser
Will MannKind Corporation outperform small cap indexesJuly 2025 PostEarnings & Capital Efficient Trading Techniques - خودرو بانک
MannKind at Wells Fargo Conference: Strategic Diversification Unveiled - Investing.com
MannKind Corporation recovery potential after sell offTrade Exit Summary & Community Consensus Trade Signals - Newser
MannKind stock price target raised to $11 by H.C. Wainwright on Tyvaso success - Investing.com
MannKind (MNKD) Expands United Therapeutics Deal Can New Platform Revenues Transform Its Long-Term Story? - simplywall.st
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump - simplywall.st
Can MannKind Corporation recover in the next quarterWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Published on: 2025-09-03 02:55:27 - Newser
Forecasting MannKind Corporation price range with options dataIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Combining machine learning predictions for MannKind CorporationJuly 2025 Recap & Safe Capital Investment Plans - Newser
Can MannKind Corporation ride the EV waveShare Buyback & Target Return Focused Picks - خودرو بانک
Trend analysis for MannKind Corporation this weekMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Does MannKind Corporation show high probability of reboundJuly 2025 Breakouts & Real-Time Market Trend Scan - Newser
Historical volatility pattern of MannKind Corporation visualized2025 Market Overview & Smart Allocation Stock Reports - Newser
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
Is MannKind Corporation stock a buy or sellQuarterly Performance Summary & Low Drawdown Momentum Ideas - خودرو بانک
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 - MSN
Applying chart zones and confluence areas to MannKind CorporationPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
What MACD and RSI say about MannKind CorporationMarket Sentiment Review & Verified Momentum Watchlists - Newser
Mannkind (MNKD) Surges 25% on Strategic Acquisition and Financing Hints – What’s Next? - AInvest
Full technical analysis of MannKind Corporation stockJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):